BACKGROUND: The present study was designed to determine whether circulating leptin concentrations and/ or body mass index (BMI) in women undergoing IVF are predictive of outcomes. METHODS: IVF cycle outcomes, e.g. fertilization, embryo development, implantation, pregnancy, were analysed relative to baseline (i.e. day gonadotrophin stimulation was initiated) non-fasting serum leptin concentrations and BMI. RESULTS: Serum leptin concentrations correlated with BMI (r ⍧ 0.739, P < 0.0001) as expected. Multiple logistic regression analyses showed correlation between serum leptin and pregnancy success (likelihood ratio ⍧ 5.198, P < 0.05), but there was no association between pregnancy and BMI. However, the serum leptin to BMI ratio was more strongly correlated (likelihood ratio ⍧ 7.258, P Ͻ 0.01) with pregnancy success than was leptin alone. Moreover, women with a low leptin:BMI ratio (≤0.3) had significantly more superior quality embryos on day 3 post-retrieval (2.5 versus 1.4, P < 0.05, Kruskal-Wallis) and a greater implantation rate (26.7 versus 13.2%, P < 0.025, χ 2 ) than women with a high leptin:BMI ratio (≥0.7). CONCLUSIONS: The leptin:BMI ratio appears to be highly predictive of IVF success. Elevated leptin concentrations, particularly relative to BMI, may negatively impact fertility by assisted reproduction, possibly through direct ovarian actions resulting in impaired oocyte quality and/or early embryo development.
Introduction
Leptin is a peptide hormone secreted by adipocytes. Circulating concentrations of leptin correlate strongly with parameters of body adiposity, such as body mass index (BMI). In addition to a wealth of data indicating centrally-mediated effects of leptin on the reproductive axis (Clarke and Henry, 1999) , more recent evidence has revealed a potential role for leptin as a direct regulator of ovarian function. Leptin modulates gonadotrophin ϩ insulin-or insulin-like growth factor (IGF)-stimulated steroidogenesis by bovine Francisco, 1997, 1998) , rat (Zachow and Magoffin, 1997) , and human (Karlsson et al., 1997; Brannian et al., 1999) follicular cells. Leptin and its receptor are expressed in the human ovary (Cioffi et al., 1997; Karlsson et al., 1997) . Moreover, leptin has been immunocytochemically localized in human oocytes and early cleaving embryos Cioffi et al., 1997) . Expression of leptin receptor mRNA and protein has been confirmed in mouse metaphase II stage oocytes, and leptin can activate leptin receptor-associated signal transduction pathways in these oocytes (Matsuoka et al., 1999) . Taken together, these results indicate that follicular cells, oocytes, and early pre-implantation embryos may be targets of direct leptin action. The exact role of leptin in normal ovarian physiology and its impact on assisted reproduction remains to be elucidated.
Several recent studies have investigated the impact of leptin in assisted reproduction cycles. For example, circulating leptin concentrations reportedly increase during gonadotrophin stimulation for IVF, apparently enhanced by the high oestradiol concentrations experienced during IVF cycles (Strowitski et al., 1998; Butzow et al., 1999; Zhao et al., 2000) . It was shown in one study (Butzow et al., 1999) that a large relative increase in leptin was associated with diminished ovarian response to gonadotrophin. Furthermore, leptin may influence outcomes from IVF. In a recent report (Mantzoros et al., 2000) , patients who became pregnant from IVF had lower mean follicular fluid concentrations of leptin than patients who did not become pregnant. Follicular fluid leptin concentrations have been negatively correlated with intrafollicular oxygen tension (Barroso et al., 1999) , which may negatively impact oocyte development and maturation. The objective of the present study was to determine whether IVF outcomes (e.g. fertilization, embryo development, implantation, and pregnancy) correlate with serum leptin concentration and/or BMI.
Materials and methods

Study population
One hundred and seventytwo IVF cycles (n ϭ 139 patients) were retrospectively (n ϭ 128) or prospectively (n ϭ 44) included in the study, which was approved by the University of South Dakota Institutional Review Board. Patient age ranged from 23-39 years (32.3 Ϯ 3.9, mean Ϯ SD). Patients Ͼ39 years were excluded, as were patients with a diagnosis of polycystic ovarian syndrome (PCOS) on the basis of (i) a history of oligo-or amenorrhoea due to chronic anovulation, and (ii) a mild elevation in serum testosterone (80-200 ng/d) and/or a free androgen index Ͼ8.5. The latter were excluded since leptin physiology may be altered in PCOS patients (Jacobs and Conway, 1999) . All patients were suppressed with luteal phase GnRH agonist (Lupron ® ; TAP Pharmaceuticals, Abbott Park, IL, USA) prior to stimulation with purified urinary FSH (uFSH; Metrodin ® ; Serono, Randolph, MA, USA) or recombinant FSH (FSHr; Gonal-F ® ; Serono, or Follistim ® ; Organon, West Orange, NJ, USA) or human menopausal gonadotrophin (HMG, Repronex ® ; Ferring Pharmaceuticals, Tarrytown, NY, USA, or Pergonal ® ; Serono) for 6.5-13.5 days. Patients were injected with 10 000 IU human chorionic gonadotrophin (HCG, Profasi ® ; Serono) 34 h before oocyte retrieval by transvaginal ultrasound-guided follicular aspiration. Fertilized zygotes were cultured in P-1 medium (Irvine Scientific, Santa Ana, CA, USA) supplemented with 10% synthetic serum substitute (SSS; Irvine Scientific). Embryos cultured beyond day 3 post-retrieval were transferred to blastocyst medium (Irvine Scientific) with 10% SSS. All embryo transfers were intrauterine. Serum samples were collected between 0800 and 1000 h from non-fasting patients on the first day of gonadotrophin treatment. Oestradiol was measured in 200 µl of fresh serum, and the remainder of each serum sample was frozen and stored at -20°C for later assay of leptin. BMI was calculated from patients' height and weight recorded at the beginning of each cycle.
Assays
Serum leptin concentrations were measured by homologous radioimmunoassay using a human leptin radioimmunoassay kit (Linco Research Inc., St Charles, MO, USA) as previously described (Zhao et al., 2000) . Duplicate 100 µl-volumes of serum were assayed for each sample. High and low end quality control specimens were placed at the beginning and the end of each assay. Inter-and intra-assay coefficients of variation were Ͻ8% at all concentrations. Serum oestradiol concentrations were measured using the DPC Immulite System ® (Diagnostic Products Corp., Los Angeles, CA, USA) in a clinical laboratory according to standard protocol.
Data collection
Demographic and IVF cycle outcome data were recorded from patient charts and laboratory database. Data included female and male diagnoses, peak oestradiol concentrations, type of insemination (i.e. IVF or ICSI), number of mature (metaphase II) oocytes retrieved, fertilization and cleavage rates, embryo development on postretrieval day 3 (mean number of blastomeres), number of superior quality embryos on day 3 post-retrieval (defined as eight blastomeres of equal size with good to excellent morphology), and blastocyst formation rate. Implantation rate was defined as the number of gestational sacs visible on ultrasound expressed per number of embryos transferred. In all cases, pregnancy rate is defined based on the presence of at least one gestational sac visible on ultrasound expressed per cycle (only cycles with a fresh embryo transfer were included in the study).
Statistical analyses
Unless otherwise indicated, all results are based on first attempt IVF cycles only. Thirty patients had repeat IVF cycles, and these were analysed separately. Statistical analyses were performed using SigmaStat 2.0 software (SPSS Inc., Chicago, IL, USA). Multiple logistic regression analyses were initially used to determine overall relationships among serum leptin concentration, BMI, and pregnancy rate. Based upon logistic regression analyses, patients were categorized by serum leptin:BMI ratio (see Results). Normally distributed parametric data were analysed by analysis of variance (ANOVA). Categorical data and parametric data that did not show normal distribution were analysed by χ 2 or Kruskal-Wallis test as appropriate. When significance was found, ANOVA and Kruskal-Wallis tests were followed by Duncan's or Dunn's post-hoc tests respectively. Significance was assumed at P ഛ 0.05 for all tests.
Results
A significant correlation (r ϭ 0.739, P Ͻ 0.0001) between baseline serum leptin concentration and BMI was evident ( Figure 1 ) as expected. Overall first cycle pregnancy rate in the study population was 38.8% (54/139). Visual inspection of the data suggested that (i) patients having IVF cycles that resulted in a clinical pregnancy tended to have lower serum leptin concentrations, and (ii) the majority of IVF cycles resulting in pregnancy had leptin-BMI co-ordinates that fell below the regression line. The latter observation suggested the possibility that the ratio of leptin to BMI might predict pregnancy success. Multiple logistic regression analyses confirmed these observations (Table I) . Whereas serum leptin concentration significantly correlated with pregnancy success (P ϭ 0.023), the serum leptin to BMI ratio showed a stronger relationship (P Ͻ 0.01). In contrast, BMI alone did not correlate with pregnancy outcome (P Ͼ 0.50, non-significant).
As suggested by regression analysis, a progressive decline in pregnancy rate occurred with increasing serum leptin:BMI ratio ( Figure 2 ). A dramatic difference in pregnancy rate was evident between the lowest (0.1-0.2) leptin:BMI group compared to the highest (Ͼ0.8) leptin:BMI group (57.9 versus 15.0%, P Ͻ 0.01, χ 2 ). The data suggest that a leptin:BMI ratio ജ0.7 may represent a threshold predictive of poorer pregnancy success.
To investigate further the relationship between the leptin:BMI ratio and IVF outcomes, patient cycles were grouped into three categories, low (0.1-0.3), moderate (0.4-0.6), and high (ജ0.7) leptin:BMI. Three categories were chosen rather than five to increase statistical power. The three groups were matched by patient age, female diagnoses, incidence of male infertility, use of intracytoplasmic sperm injection (ICSI), and type of gonadotrophin used for stimulation (Table II) . Baseline nonfasting serum leptin and BMI differed among all three groups.
Comparison of IVF cycle outcomes among groups is shown in Table III . There were no differences in peak oestradiol concentration, number of mature oocytes retrieved, number of oocytes fertilized with two pronuclei (PN), fertilization rate, cleavage rate, or mean developmental stage on the morning of day 3 post-retrieval. However, there were on average, significantly more superior quality embryos on day 3 in the low leptin:BMI group than in the high leptin:BMI group. This was reflected in a significantly higher implantation rate in the low (26.7%) versus high (13.2%) group. This was true for both day 3 and day 5 or 6 embryo transfers, although the difference appeared to be more dramatic for the blastocyst (day 5/6) transfers (Table III) . Despite more superior quality embryos on day 3, the blastocyst formation rate did not differ significantly among groups. The only available measure of uterine status was endometrial thickness on the day of HCG administration, which was consistent among groups. Moreover, the miscarriage rate did not show significant differences among groups, although statistical power was very low. Overall pregnancy rate in the low group (48.8%) was nearly twice that in the high (25.0%) leptin:BMI group, as was the live birth rate (40.5 versus 17.5%). Similar trends were evident when pregnancy rates were expressed on the basis of day of embryo transfer or type of gonadotrophin used, although there was no statistical significance (Table III) . Incidence of multiple pregnancies did not differ among leptin:BMI groups.
Thirty patients in the study population underwent more than one IVF cycle. Comparison of pregnancy success in first and second cycles is shown in Table IV . Because of the small number of patients in this comparison, cycles were categorized only as having a leptin:BMI ratio greater or less than 0.7. In 22 cases, patients had similar leptin:BMI ratios in both cycles (Table IVA) . The cumulative pregnancy rate after two cycles was over 50% for the Ͻ0.7 group, but none of seven patients with leptin:BMI over 0.7 became pregnant after two cycles. Three of the latter patients had a third cycle, and none became pregnant. In eight cases, the leptin:BMI ratio was greater than 0.7 for one cycle, but less than 0.7 for the other cycle (Table IVB) . Three of eight patients became pregnant in their Ͻ0.7 cycle, but only one of eight became pregnant in their Ͼ0.7 cycle.
In addition, 52 frozen embryo transfers were subsequently performed in women included in the study. As shown in Table  V , patients whose leptin:BMI ratio was Ͻ0.7 in their fresh IVF cycle tended to have better cleavage of pronuclear thawed embryos, and better implantation and pregnancy rates.
Discussion
This is the first report of a strong predictive relationship between baseline non-fasting serum leptin:BMI ratio and IVF outcomes. The results confirm earlier reports that leptin may influence fertility, at least in assisted reproduction cycles. The current data expand upon this relationship by demonstrating that the ratio of leptin to BMI is more strongly correlated with pregnancy success than is leptin concentration alone. This implies that leptin secretion and/or action is modulated by factors other than adiposity that impact fertility. A greater proportion of fertilized oocytes developing into superior quality embryos by day 3 suggests that the effect of leptin may be on oocyte quality and/or embryo development. This is supported by diminishing implantation rates with higher leptin:BMI ratio, although a uterine effect can not be ruled out.
A negative relationship between follicular fluid concentrations of leptin and IVF pregnancy success was recently reported (Mantzoros et al., 2000) . However, these authors found no association between pregnancy success and serum leptin concentrations, in contrast to the present data. This was somewhat surprising since serum and follicular fluid concentrations of leptin have been shown to be similar (Butzow et al., 1999; Zhao et al, 2000) . Leptin was measured in serum at the end of gonadotrophin stimulation in the former study, whereas serum leptin was measured prior to stimulation in the present study. Serum leptin concentration has been reported to increase during gonadotrophin stimulation in association with rising oestradiol concentrations (Strowitski et al., 1998; Zhao et al., 2000) . This may partly account for the difference in results between the two studies.
The present results demonstrate a stronger relationship between leptin and pregnancy success when leptin concentrations are expressed relative to BMI, i.e. the leptin:BMI ratio. The coefficient of determination (r 2 ϭ 0.546) for the linear regression analysis of leptin versus BMI indicates that only about half of the variability in leptin concentrations in this patient population was related to BMI. Therefore the stronger correlation between pregnancy success and leptin:BMI ratio may suggest that other determinants of leptin variability influence pregnancy outcome independently or interactively with leptin. When circumstances exist that elevate leptin concentrations more than would be predicted by body mass alone, fertility may be more greatly impacted. Conversely, when leptin concentrations are less than predicted by body mass, fertility may still be good even in obese patients. This 1822 is supported by the data in that several patients with BMI ജ30, i.e. obese, became pregnant if their serum leptin concentration was less than predicted by the regression equation. However, very few patients became pregnant when their baseline leptin was ജ30 ng/ml, even if their BMI was relatively low.
Many factors have been shown to influence leptin secretion in animal and human models, including insulin (Kolaczynski et al., 1996; Carmina et al., 1999) , and glucose metabolism (Chin-Chance et al., 2000; Wellhoener et al., 2000) . Recent studies in human subjects (Chin-Chance et al., 2000; Wellhoener et al., 2000) have provided compelling evidence that energy balance, i.e. caloric intake, is a major determinant of leptin secretion, and affects circulating leptin concentrations more than serum insulin or glucose concentrations (Wellhoener et al., 2000) . It's possible that women may be able to improve their fertility through dietary and lifestyle modifications that lower circulating leptin concentrations.
High concentrations of oestrogen experienced during gonadotrophin stimulation cycles are associated with elevated leptin concentrations (Strowitzki et al., 1998; Zhao et al., 2000) . In a preliminary study of 35 IVF cycles included in the final study, serum leptin was measured on the day of HCG administration. Pregnancy success appeared to be more closely associated with baseline leptin concentrations than with stimulated concentrations, although the two were very strongly correlated. Butzow et al. (1999) reported that a large relative increase in leptin concentrations during gonadotrophin stimulation was associated with diminished ovarian response (Butzow et al., 1999) . Pregnancy rates in our preliminary study were very similar in patients whose leptin increased by 20% or more (26/35; pregnancy rate ϭ 30.8%) versus those whose leptin remained relatively unchanged (9/35; pregnancy rate ϭ 33.3%; unpublished data). It remains to be elucidated how elevated leptin concentrations negatively impact IVF outcomes. Since there was no effect of leptin on the number of mature oocytes retrieved, number of fertilized zygotes or fertilization rate, diminished outcomes in patients with high leptin:BMI ratios would appear to be a function of post-fertilization events (e.g. embryo development, ability of embryos to implant, or uterine receptivity), although these may be pre-determined if oocyte development or maturation are impaired. The fact that patients with a high leptin:BMI ratio had fewer superior quality embryos on day 3 post-retrieval, despite starting out with the same number of fertilized zygotes, suggests an effect on oocyte developmental competence and/or embryo development.
Several pieces of evidence suggest that leptin may affect folliculogenesis and thus oocyte development. Leptin can modulate follicular steroidogenesis (Karlsson et al., 1997; Francisco, 1997, 1998; Zachow and Magoffin, 1997; Brannian et al., 1999; Kitawaki et al., 1999) and a strong inverse correlation was demonstrated between follicular fluid leptin concentrations and intrafollicular oxygen concentration (Barroso et al., 1999) . Moreover, leptin may have direct receptor-mediated actions on developing oocytes. Although leptin receptor expression at the molecular concentration has
apparently not yet been confirmed in human oocytes, mouse metaphase II (MII) and germinal vesicle (GV) stage oocytes express both mRNA and protein of the long isoform (OB-Rl) of the leptin receptor (Matsuoka et al., 1999) . Physiological concentrations of leptin resulted in tyrosine phosphorylation (i.e. activation) of STAT3 in mouse MII oocytes (Matsuoka et al., 1999) . Moreover, leptin and STAT3 exhibit polarized co-localization in human oocytes and early cleaving embryos (Cioffi et al., 1997; Antczak and Van Blerkom, 1997) , and leptin induced activation of mitogen-activated protein kinase (MAPK) in a mouse embryonic cell line (Takahashi et al., 1997) . Taken together, these results support the view that leptin is a physiological regulator of oocyte developmental competence acting indirectly via the follicle and directly via actions on the oocyte. It is therefore quite possible that elevated leptin concentrations might have a negative impact on oocyte developmental competence in IVF cycles. Impaired uterine receptivity is also possible. Human endometrium expresses leptin receptor (Alfer et al., 2000; Kitawaki et al., 2000) . Although the presence of leptin was not obligatory for implantation in mice (Mounzih et al., 1998) , the effect of high leptin on endometrial receptivity and implantation is unknown. In the present study, uterine receptivity was not directly evaluated. Endometrial thickness was not related to serum leptin concentration or leptin:BMI ratio, and the 1824 miscarriage rate was similar in all groups. Moreover, cleavage and implantation rates in frozen embryo transfer cycles were lower in women with high leptin:BMI in their fresh cycle, suggesting that either embryo quality was impaired or that endometrial receptivity was poor in both fresh and frozen embryo transfer cycles. The data would seem to favour an embryonic origin in explaining the reduced implantation associated with elevated leptin, but the effect of leptin on uterine receptivity and placentation requires investigation.
Data from repeat IVF cycles suggest that women with a low leptin:BMI ratio have a high probability of pregnancy success during second IVF attempts if their first cycle was unsuccessful. In contrast, women with a high leptin:BMI ratio had very poor success in repeat cycles. Thus the leptin:BMI ratio may be very useful in counselling patients considering repeat IVF attempts. Remarkably in the eight women who had repeat cycles in which their leptin:BMI ratio differed from their first cycle, pregnancy success appeared to be better in the cycles with the lower leptin:BMI ratio. Confirmation of this in a larger cohort of patients would provide hope that women may be able to improve their chances of pregnancy by lowering their leptin concentrations, possibly through dietary and lifestyle modifications, before repeated attempts at IVF.
An important consideration in interpreting the results of this study is that only single, non-fasting measurements of serum leptin were made during each IVF cycle. Leptin variability derives primarily from body fat mass and exhibits a wide range of physiological concentrations from 1-2 ng/ ml up to well over 50 ng/ml. Within the context of the intersubject variation, leptin concentrations within an individual vary over time, dependent upon circadian and ultradian patterns of secretion and fed state. Although serum samples were drawn at the same time of day (0800-1000 h), patients were not instructed to fast. In general, the normal within-individual diurnal variations are of a much smaller magnitude than the inter-individual variation determined by significant differences in body adiposity. The relative fluctuation between minimum and maximum daily concentrations appears to be somewhere between 21% (Schoeller et al., 1997) and about 50% (Boden et al., 1997; van Aggel-Leijssen et al., 1999) . Considine et al. (1996) reported no significant change in serum leptin before or after regular meals , although in a larger study leptin increased on average about 25% within 6 h following a high calorie meal (Dallongeville et al., 1998) . Leptin secretion also follows ultradian pulsatile patterns in men and women (Licinio et al., 1998) . Leptin pulse amplitude in women, although greater than in men, is generally Ͻ50% (Licinio et al., 1998; Sir-Peterman et al., 1999) . Mean baseline non-fasting serum leptin concentrations in low versus high leptin:BMI groups in the present study population differed by nearly five-fold. Variations in leptin concentrations due to secretory pulsatility or pre-versus post-prandial conditions cannot account for the large differences between patient groups. Moreover, all serum specimens were drawn between 0800 and 1000 h, which is the time of day when circulating leptin concentrations would be expected to be at their nadir (Schoeller et al., 1997; van Aggel-Leijssen et al., 1999) . Therefore it seems highly unlikely that diurnal variation in leptin concentrations had a significant impact on the correlation between leptin:BMI and implantation and pregnancy outcomes observed in the present study. Nevertheless confirmation of these results in a controlled prospective study comparing IVF outcomes with fasting leptin concentrations is warranted.
There are other limitations to this study. For example, not all patients received the same type of gonadotrophin and dosages varied, although the three leptin:BMI groups were proportionate for each type and duration of stimulation. Moreover, some patients had blastocyst transfers (day 5 or 6) whereas most had day 3 embryo transfers. Trends in pregnancy rates among leptin:BMI patient groups were not altered by gonadotrophin type or day of embryo transfer, although the limited data suggests the possibility of a greater impact of elevated leptin on implantation and pregnancy outcomes in blastocyst transfers.
In summary, baseline non-fasting serum leptin:BMI ratio appears to be highly predictive of IVF outcomes. The data suggest that elevated leptin has a negative impact on oocyte and/or embryo quality leading to impaired implantation and reduced probability of pregnancy success. Confirmation of this relationship may assist clinicians in counselling patients and improving the success of assisted reproduction.
